Preclinical efficacy and safety evaluation of BD211 autologous CD34+ hematopoietic stem cell injection for transfusion-dependent β-thalassemia in NCG-X mice
The no observed adverse effect level of BD211 was established at 1.2 × 10<sup>6</sup> cells per mouse. BD211 shows potential as a safe therapeutic approach for treating transfusion-dependent thalassemia.
Authors
- Xuedong Dai (ORCID: https://orcid.org/0000-0001-8211-2660)
- Zhonghai Li (ORCID: https://orcid.org/0000-0003-4735-1193)
- Sikai Ling
- Quanjun Wang (ORCID: https://orcid.org/0000-0002-8087-2727)
- Qi Wang (ORCID: https://orcid.org/0000-0002-1728-8763)
- Shuang Chen (ORCID: https://orcid.org/0000-0002-3220-3262)
- Ying Huang (ORCID: https://orcid.org/0009-0002-4674-0218)
Institutions
- Peking University (CN)
- NewGen Therapeutics (United States) (US)
Publication Details
- Journal
- Frontiers in Cell and Developmental Biology
- Published
- 2025-06-16
- DOI
- https://doi.org/10.3389/fcell.2025.1607707
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00